Previous 10 | Next 10 |
2024-04-03 01:10:40 ET Summary Annexon, Inc. is a clinical stage biotech company that is close to releasing topline data on its lead therapy, ANX005. ANX005 has the potential to become the first FDA approved therapy for Guillain-Barré syndrome (GBS). GBS is a rare disease...
2024-04-01 08:53:49 ET More on the markets My Current View Of The Market: April 2024 Edition (Technical Analysis) SPY: Potential, Yes, But Risks Ahead Too Where This Market Is Going (Technical Analysis) Investors are sellers of fund assets for the second cons...
2024-04-01 07:30:05 ET Wells Fargo analyst issues OVERWEIGHT recommendation for ANNX on April 1, 2024 05:50AM ET. The previous analyst recommendation was Overweight. ANNX was trading at $7.17 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-04-01 07:00:05 ET Derek Archila from Wells Fargo issued a price target of $12.00 for ANNX on 2024-04-01 05:50:00. The adjusted price target was set to $12.00. At the time of the announcement, ANNX was trading at $7.17. ANNX currently trades -14.64% versus its 52 wee...
2024-03-28 12:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-26 17:28:35 ET More on Annexon Biosciences Seeking Alpha’s Quant Rating on Annexon Biosciences Historical earnings data for Annexon Biosciences Financial information for Annexon Biosciences Read the full article on Seeking Alpha For fur...
2024-03-26 16:44:07 ET More on Annexon Biosciences Seeking Alpha’s Quant Rating on Annexon Biosciences Historical earnings data for Annexon Biosciences Read the full article on Seeking Alpha For further details see: Annexon Biosciences GAAP EPS of ...
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024, a Global Sham-Controlled Trial Using Vision Preservation as Primary Outcome Measure ...
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
2024-03-21 16:58:21 ET Gainers: Adicet ( ACET ) +5% . The Honest Company ( HNST ) +5% . Sagimet Biosciences ( SGMT ) +3% . National CineMedia ( NCMI ) +3% . Annexon ( ANNX ) +3% . Losers: lululemon athletica...
News, Short Squeeze, Breakout and More Instantly...
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation BRISBANE, Calif., July 11, 2024 (GLOBE N...
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increa...
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005 Has Potential to be the First Targeted Therapy Approved for the Treatment of GBS BRISBANE, Calif., June 18, 2024 (GLOBE...